AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04388332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Structural allograft
Description: Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips
Study NCT04388332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tritanium C
Description: Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
Study NCT04111497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Given PO
Study NCT04054167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy
Description: Undergo ultra low dose radiation
Study NCT00420680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
Study NCT00420680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
Study NCT00420680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
Study NCT03736265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
Study NCT03020914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Distraction
Description: watching a movie using video glasses and headphones
Study NCT03284957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT03284957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT03284957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03284957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Pharmaceutical form: tablet
Study NCT02661828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two-Week Antidepressant Taper Regimen
Description: Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
Study NCT04607772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Dose: 12 mg/kg
Study NCT02661828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-Week Antidepressant Taper Regimen
Description: Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
Study NCT04607772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Dose: 200, 400, 600, 800 mg
Study NCT01936259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Stem
Description: The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.
Study NCT01936259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano
Description: The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
Study NCT04184076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) with dietary counseling
Description: 1. Subjects will be instructed to administer time-restricted feeding.~2. Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~3. Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data.
Study NCT01961869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast release BRB confection
Description: Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
Study NCT01961869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermed release BRB confection
Description: Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
Study NCT01961869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolong release BRB confection
Description: Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
Study NCT03513029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VytronUS Ablation System
Description: Catheter Ablation for Paroxysmal Atrial Fibrillation
Study NCT02046434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol Phenylbutyrate
Study NCT04670016 — intervention group
Intervention type: OTHER
Intervention: This study does not include an intervention.
Description: This study does not include an intervention.
Study NCT00763542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for SUD
Description: CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
Study NCT00763542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for SUD
Description: CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
Study NCT00763542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured writing therapy for PTSD
Description: Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
Study NCT04607772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose: 1000 mg/m\^2
Study NCT04607772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose: 100 mg/m\^2
Study NCT01956175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pharyngeal stimulation
Description: Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
Study NCT01956175 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
Study NCT01251796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197 and Erlotinib
Description: Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
Study NCT02826889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Intelivue MP70 monitor
Description: Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
Study NCT02826889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleth Variability Index (PVI)
Description: PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
Study NCT03511560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended Release Oral Tablet
Description: Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
Study NCT03511560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
Study NCT01542866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Management Tool (HMT)
Description: Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
Study NCT03251924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986226
Description: specified dose on specified days
Study NCT03251924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study NCT03251924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: specified dose on specified days
Study NCT03251924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Vaccine
Description: specified dose on specified days
Study NCT01544244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GSC physical therapy
Description: Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
Study NCT01544244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
Study NCT03169153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
Study NCT03169153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon C contact lenses
Description: Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
Study NCT02327208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT02327208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Study NCT02327208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Study NCT01301248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation plus Cetuximab
Description: Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
Study NCT01301248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
Study NCT00529165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection-meal-interval
Description: The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks.
Study NCT00806416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium (+) cholecalciferol
Description: A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
Study NCT00806416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: alendronate
Description: A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
Study NCT01464528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronan
Description: single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
Study NCT05404516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year.
Study NCT05404516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3.
Study NCT05404516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3.
Study NCT05404516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3.
Study NCT05404516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3.
Study NCT00806416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparator: cholecalciferol (Vitamin D)
Description: A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
Study NCT01906801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Study NCT02203591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep C
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study NCT02203591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep CH
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study NCT02203591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study NCT02203591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study NCT05210036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Therapy (US)
Description: All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist.
Study NCT05210036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Laser Therapy (HILT)
Description: All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist.
Study NCT02290587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI - Clinical and cognitive evaluation
Description: Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention
Study NCT01906801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine sulfate
Study NCT01906801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Study NCT01906801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Diacerein)
Description: Sugar pill manufactured to mimic Diacerein 50 mg tablet
Study NCT02290587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT03428776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Compliance-linked incentives
Description: Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
Study NCT03428776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intelligent Compliance-linked incentives
Description: Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
Study NCT03428776 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Record keeping
Description: Electronic immunization records on cloud-based software platform and use of biometric identification
Study NCT00861419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg PO (BID)
Study NCT00861419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 125 mg PO (QD)
Study NCT00861419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 75 mg PO (QD)
Study NCT00861419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 10 mg/kg IV (QW)
Study NCT00861419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg PO (QD)
Study NCT00861419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg IV Q3W
Study NCT00861419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 3 mg/kg IV (QW)
Study NCT04707235 — intervention group
Intervention type: DRUG
Intervention: Hydroxycarbamide
Description: Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
Study NCT04104139 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT04104139 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04104139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT00793442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection and Assays
Description: The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
Study NCT04034589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib combined with fulvestrant
Description: Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days